<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32236980</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-3083</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the European Academy of Dermatology and Venereology : JEADV</Title>
          <ISOAbbreviation>J Eur Acad Dermatol Venereol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Successful treatment of Pachyonychia congenita with Rosuvastatin.</ArticleTitle>
        <Pagination>
          <StartPage>e480</StartPage>
          <EndPage>e482</EndPage>
          <MedlinePgn>e480-e482</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jdv.16393</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Frommherz</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-1384-7844</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Has</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-6066-507X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Eur Acad Dermatol Venereol</MedlineTA>
        <NlmUniqueID>9216037</NlmUniqueID>
        <ISSNLinking>0926-9959</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>83MVU38M7Q</RegistryNumber>
          <NameOfSubstance UI="D000068718">Rosuvastatin Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053549" MajorTopicYN="Y">Pachyonychia Congenita</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068718" MajorTopicYN="N">Rosuvastatin Calcium</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32236980</ArticleId>
        <ArticleId IdType="doi">10.1111/jdv.16393</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Samuelov L, Smith FJD, Hansen CD, Sprecher E. Revisiting pachyonychia congenita: a case-cohort study of 815 patients. Br J Dermatol 2020; 182: 738-746.</Citation>
        </Reference>
        <Reference>
          <Citation>Goldberg I, Fruchter D, Meilick A, Schwartz ME, Sprecher E. Best treatment practices for pachyonychia congenita. J Eur Acad Dermatol Venereol 2014; 28: 279-285.</Citation>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Hickerson RP, Schwartz ME et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010; 18: 442-446.</Citation>
        </Reference>
        <Reference>
          <Citation>Hickerson RP, Leake D, Pho LN, Leachman SA, Kaspar RL. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci 2009; 56: 82-88.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdollahimajd F, Rajabi F, Shahidi-Dadras M et al. Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br J Dermatol 2019; 181: 584-586.</Citation>
        </Reference>
        <Reference>
          <Citation>Leachman SA, Kaspar RL, Fleckman P et al. Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 2005; 10: 3-17.</Citation>
        </Reference>
        <Reference>
          <Citation>Funk T, Hansen CD, Paller A, O'Toole EA. Update on pachyonychia congenita research. Br J Dermatol 2020; 182: 788-789.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Gartner U, Smith FJ, McLean WH. Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol 2011; 131: 1045-1052.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee SJ, Qin H, Benveniste EN. Simvastatin inhibits IFN-gamma-induced CD40 gene expression by suppressing STAT-1alpha. J Leukoc Biol 2007; 82: 436-447.</Citation>
        </Reference>
        <Reference>
          <Citation>Atzmony L, Lim YH, Hamilton C et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy. J Am Acad Dermatol 2020; 82: 123-131.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
